Product Details
Synonym
CTLA4, CD152
Source
Human CTLA-4 Protein, Twin-Strep Tag (CT4-H5284) is expressed from human 293 cells (HEK293). It contains AA Ala 37 - Phe 162 (Accession # P16410-1).
Predicted N-terminus: Ala 37
Request for sequenceMolecular Characterization

Other Tags and Version Biotin & Other Labeled Version
This protein carries a twin strep tag at the C-terminus.
The protein has a calculated MW of 16.5 kDa. The protein migrates as 20-30 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin
Less than 1.0 EU per μg by the LAL method / rFC method.
Purity
>85% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE

Human CTLA-4 Protein, Twin-Strep Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 85% (With Star Ribbon Pre-stained Protein Marker).
Bioactivity-ELISA

Immobilized Human B7-2, Fc Tag, premium grade (Cat. No. CD6-H5257) at 2 μg/mL (100 μL/well) can bind Human CTLA-4 Protein, Twin-Strep Tag (Cat. No. CT4-H5284) with a linear range of 1-20 ng/mL (QC tested).
Protocol
Customer Reviews Writing Reviews

Background
Recent Advances
- English Name:
Cytotoxic T-Lymphocyte-Associated Antigen 4
- Category:
- Approved Drugs:
5 Details
- Drugs in Clinical Trials:
65 Details
- Highest Development Stage:
Approved
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521




















